Blood Cancers | Tumor

My Feeling of Survivor’s Guilt

June 19th 2024, 5:00pm

Article

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

FDA-Approved Rytelo a ‘Game Changer’ for Some Patients with MDS

June 17th 2024, 1:00pm

Article

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

FDA Approves Rytelo for Some With Low- to Intermediate-1-risk MDS

June 7th 2024, 1:23pm

Article

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Reblozyl Continues to Improve MDS Transfusion Independence

June 3rd 2024, 7:00pm

Article

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

Safety Profile of Lower-Dose Oral Onureg Remains Consistent in Lower-Risk MDS

June 3rd 2024, 1:00pm

Article

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.

Cancer and Fatigue Go Together

May 15th 2024, 5:00pm

Article

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Cancer

May 10th 2024, 9:23pm

Article

When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.

Social Support Is Key During BiTE Therapy for Blood Cancers

May 9th 2024, 7:30pm

Video

An oncology nurse discusses what patients should know before BiTE therapy, and what they can do if they do not have a social support system.

Nurse Says CAR-T Cell Therapy is a ‘Mind-Blowing’ Advancement

May 3rd 2024, 1:00pm

Video

For patients with blood cancers, CAR-T cell therapy has been a “mind-blowing” advancement for treatment in the cancer space.

Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis

April 16th 2024, 7:00pm

Article

Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.